News and articles

Biosimilar switching is becoming more common as Rituximab, Trastuzumab and Bevacizumab all have biosimilars on the market. Due to stock shortages and contract prices, there may be a need to switch biosimilars more regularly. This will become more common as additional biosimilar products come to the market. iQemo can facilitate biosimilar switching through several mechanisms.

Beyond the standard benefits of e-prescribing, iQemo provides many additional features that will help your organisation further improve the safety of its patients receiving chemotherapy.

An explanation of the iQemo settings hierarchy, from drug-formulary to drug-level, and how that relates to dose capping.

Research by members of BOPA uncovers the clear need to streamline, standardise and share regimens across a national library.

Enhancing patient safety and reducing the burdens on clinical staff, with end-to-end administration tracking through label printing and barcode scanning support in the iQemo prescribing platform.

Mid Cheshire NHS Foundation Trust complete their training to adopt iQemo, a move that takes them from a desktop-based system to the cloud-hosted, end-to-end chemotherapy prescription and management platform.

Wrightington, Wigan and Leigh NHS Foundation Trust is the latest NHS Trust to go live – on time, and on budget – with the iQemo electronic SACT platform.